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Abstract
Objective: Liver growth factor (LGF), a mitogen for liver cells, reduces fibrosis in a rat model of cirrhosis. The present study assesses the
possible vascular antifibrotic and antihypertensive effects of LGF treatment on spontaneously hypertensive rats (SHR).
Methods: Six-month-old male SHR and normotensive Wistar Kyoto rats (WKY) were treated with LGF (4.5 Ag LGF/rat i.p. twice a week
for 2 weeks). Haemodynamic parameters were measured in anaesthetized rats. Vascular structure and function were studied in carotid arteries
using optical and confocal microscopy, radioimmunoassay for desmosine, and isometric tension recording.
Results: LGF reduced systolic and diastolic blood pressure only in SHR. When compared to those of untreated SHR, carotid arteries from
LGF-treated SHR showed: 1) a 50% reduction in collagen area and an increase in vascular smooth muscle cell number in the media, 2) no
difference in total elastin content, but an increase in size of fenestrae in the internal elastic lamina, and 3) enhanced relaxation to acetylcholine,
sodium nitroprusside, and forskolin. These effects were specific for SHR, since no changes were observed in LGF-treated WKY.
Conclusion: Short-term treatment with a low dose of LGF induced a large improvement in vascular structure and function and
significantly reduced blood pressure in a rat model of essential hypertension. The present results could open future research to
explore the vascular effects of this endogenous factor in order to determine its potential as an antifibrotic and antihypertensive agent
in humans.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Conduit arteries play a key role in the cardiovascular
system, buffering pressure pulsations during the cardiac
cycle. Increasing attention is being focused on changes of
large arteries in hypertension which increase in stiffness,
thereby loosing this buffering function [1,2]. Thus, large
artery compliance and distensibility have been shown to be
reduced in human hypertension and these alterations are
known to influence the development of complications in
hypertensive vascular disease [1–5].
The fibrous components of the extracellular matrix
(ECM), collagen and elastin, are the main elements
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 responsible for the passive vascular mechanical properties,
particularly in the aorta and its main branches, where these
proteins are abundant [1,6]. Alterations in collagen and
elastin have been well documented in hypertension and are
known to contribute to changes in vascular compliance [7–
9]. In addition, abnormalities in vascular smooth muscle
cells (VSMC), such as polyploidy [10], have been also
reported in hypertension. All these alterations create an
abnormal wall architecture, which affects, not only mechan-
ical performance, but also vasodilator function of elastic
arteries [11].
Liver growth factor (LGF), a hepatic mitogen with both
in vivo and in vitro activity, was purified by Dı ´az-Gil and
co-workers some years ago [12]. Following an in-depth
chemical and immunological study, this group demonstrated
that LGF is an albumin–bilirubin complex [13,14]. LGF is
nearly undetectable in sera from healthy humans or rats, but
its concentration is dramatically increased in the presence of
hepatobiliary disorders or liver injury [15,16]. In a model of
Cl4C-induced cirrhosis induced in rats, LGF injection
decreased total liver collagen, restored partial architectural
integrity, necrotic tissue and serum enzymes, reducing
ascites and improving hemodynamics [17].D ı ´az-Gil has
recently demonstrated that the first targets of LGF in liver
are the endothelial cells around portal spaces, which secrete
TNF-a, initiating the mitogenic pathway [18]. It is worth
noting that, in endothelial cells in vitro, LGF acts at a very
low concentration (5 pg/ml) [18], much lower than that
required for the hepatocyte growth factor (HGF) to act on
the same cells. HGF, another growth factor, the chemical
structure of which is different from that of LGF, is active in
the ng/ml range [19].
The reduction of liver fibrosis by LGF treatment leads us
to hypothesize that LGF might also exert antifibrotic actions
in other diseases, such as hypertension. Therefore, we have
investigated the vascular effects of LGF in spontaneously
hypertensive rats (SHR), a model of hypertension that
involves vascular fibrosis, abnormal wall architecture and
endothelial dysfunction [1].
2. Methods
LGF was purified from rat serum following the
procedure previously reported by Dı ´az-Gil and co-work-
ers. Purity of the LGF preparation was assessed according
to standard criteria [12,20]. LGF preparations were
lyophilized and stored at 4 -C until used, at which time,
aliquots were dissolved in saline for i.p. injection. Before
using LGF in these experiments, we checked its activity
in vivo at several doses, injecting it into normal rats to
establish the dose that produced the greatest stimulation
of liver DNA synthesis, as determined by incorporation of
3H-thymidine (New England Nuclear, Dreiech, Germany)
into DNA [12]. The optimal dose of LGF used was 4.5
Ag/rat.
2.1. LGF treatment of WKY and SHR rats
Six month old male rats were randomly divided in two
groups: LGF-treated (LGF-SHR, n=20; LGF-WKY, n=13)
and untreated (SHR, n=21; WKY, n=18). LGF treatment
was carried out as follows: LGF (4.5 Ag/rat) was injected
i.p. at 3–4 day intervals four times (days 0, 3, 6 and 9). At
day 12, haemodynamic parameters were measured in all rats
under anesthesia (50 mg/kg sodium pentobarbital i.p.),
through a cannula inserted in the right iliac artery connected
to a pressure transducer (Statham, Harvard Apparatus
GmbH, Germany). Systolic and diastolic blood pressures
(SBP, DBP, respectively) and heart rate (HR) were
measured. All procedures conformed to the Guidelines for
Care and Use of Laboratory Animals (NIH publication No.
85-23, revised in 1996; RD 223/1988).
2.2. Rat carotid artery structure
After haemodynamic parameter measurements, a group
of rats (WKY n=8, LGF-WKY n=6, SHR n=8 and LGF-
SHR n=8) was perfused with a 4% solution of paraformal-
dehyde (PFA) at a flow rate of 1 ml/min per 100 g of rat
weight for 3 h [21]. At the end of the perfusion both
common carotid arteries were dissected and kept in 4%
PFA. One of the arteries was embedded in paraffin.
Transversally cut sections were stained with Massons
trichromic method for determination of the collagen area.
The contralateral carotid artery was kept in 4% PFA and
was used to determine structural parameters (internal
diameter and media thickness), the number of VSMC in
the media, elastin content and organization of the internal
elastic lamina (IEL) by confocal microcopy. From this
second artery one ring and one longitudinal section were
obtained. Rings were stained with the nuclear dye Hoechst
33342 (10 AM) for 10 min at room temperature and washed
for 15 min. They were then visualized with a Leica TCS
SP2 confocal system (Leica Microsystems, Germany, Ex
364nm) and 10 serial optical images of the ring (1 Am thick)
were obtained with a 10 objective (for determination of
the internal diameter) and 40 (for determination of the
media thickness and VSMC number). From these serial
images, VSMC were counted with Metamorph Image
Analysis software (Universal Imaging Corporation, Down-
ingtown, PA, USA) and the total number was calculated in a
volume, taking into account media thickness of the ring. To
visualize the IEL, longitudinal sections from the carotid
arteries were mounted on a slide with the endothelial side
facing up and visualized with the 488/515 nm line of the
microscope to detect elastin (autofluorescent at this wave-
length). Stacks of serial optical sections (0.5 Am thick) were
captured from each artery with a 63 oil-immersion
objective under identical conditions of laser intensity,
brightness and contrast and a maximal projection was
obtained. Quantification of the relative area occupied by
fenestrae was performed in binary images with Metamorph
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 software [22]. In the remaining segment of carotid artery the
elastin content was estimated by radioimmunoassay for
desmosine, a crosslinked residue specific unique to elastin
[23], and total protein content assessed by ninhydrin-based
assay, as previously described [24,25].
2.3. Rat carotid artery function
Vascular function was studied in carotid arteries (WKY
n=7, LGF-WKY n=6, SHR, n=9; LGF-SHR, n=7) by
isometric tension recording [26]. Concentration-response
curves to Ach (1 nM to 100 AM), forskolin (0.1 nM to 1
AM) and sodium nitroprusside (SNP, 1 pM to 1 AM) were
then generated for endothelial-intact segments pre-con-
tracted with 0.1 AM noradrenaline (NA). All experiments
were performed simultaneously in segments from untreated
and LGF-treated SHR and WKY.
2.4. Statistical study
Comparisons between groups were made by performing
a one-way or two way analysis of variance (ANOVA), using
Graph Pad Prism 04. Post-hoc comparisons were carried out
with the Newman–Keuls test. pD2 values were calculated
by log-probit analysis according to the standard method.
Statistical significance was set at p<0.05.
3. Results
3.1. LGF treatment reduced blood pressure only in SHR.
Body weight was similar between strains, and was not
modified by treatment in either SHR or WKY rats. SBP,
DBP and HR were significantly higher in SHR when
compared to WKY. LGF treatment significantly reduced
SBP and DBP, but not HR, in SHR. However, LGF
treatment did not modify any of the haemodynamic
parameters in WKY rats (Table 1).
3.2. LGF treatment improved carotid artery structure in
SHR
LGF treatment did not change the internal diameter or
media thickness in rat carotid arteries from either WKY or
SHR (Table 2). On the other hand, in SHR LGF
significantly altered carotid artery composition, modifying
both extracellular and cellular components in the media
(Fig. 1B, C and D). Carotid collagen content was reduced by
half after LGF treatment (Fig. 1B and C). This was
paralleled by an increase in VSMC number and a reduction
in VSMC nuclear size in LGF-SHR, as compared to
untreated SHR (Fig. 1B and D). This was confirmed by
the inverse correlation observed between medial collagen
content and cell number (R
2=0.71, p<0.05). There was
also a positive correlation between collagen content and
SBP (R
2=0.83, p<0.05), as well as an inverse correlation
between VSMC number and SBP (R
2=0.6, p<0.05). In
WKY rats, collagen content was much lower when
compared to SHR, and was not modified by LGF treatment
(Fig. 1A and C). The only change induced by LGF in
carotid arteries from WKY rats was a significant increase in
cell number in the media (Fig. 1D).
LGF significantly enlarged the area occupied by fenes-
trae in the IEL of carotid arteries from SHR, but not from
WKY (Fig. 2A and B). The amount of elastin in carotid
arteries, measured by desmosine content, was significantly
greater in SHR than in WKY, although it was not
significantly modified by LGF treatment (Fig. 2C).
3.3. LGF treatment improved carotid artery vasodilator
capacity in SHR
In carotid arteries from SHR, LGF-treatment signifi-
cantly increased relaxation to the endothelium-dependent
vasodilator acetylcholine (Fig. 3A) and to the endothelium-
independent vasodilators forskolin and sodium nitroprus-
side (SNP), which stimulate cAMP and cGMP formation,
respectively (Fig. 3B and C). Concentration-response curves
to all the vasodilator agents tested were significantly shifted
to the left with a significant reduction in pD2 values and an
increase in maximal response. This effect was specific for
Table 1
Effect of LGF treatment on body weight and haemodynamic parameters in WKY and SHR
WKY (n=18) SHR (n=21) LGF-WKY (n=13) LGF-SHR (n=20)
Body weight (g) 378T9.0 389T7.3 384T13.0 405T12.9
SBP (mm Hg) 122T5.7 192T7.0
# 125T6.2 163T5.1*
DBP (mm Hg) 89T6.7 148T5.7
# 90T5.4 122T4.5*
HR (beats/min) 251T12.1 332T14.0
# 269T9.5 316T10.2
SBP, systolic blood pressure; DBP diastolic blood pressure; HR, heart rate; SHR, spontaneously hypertensive rats; WKY, Wistar Kyoto rats. Rat numberi s
indicated in parentheses. * p<0.01 LGF-treated SHR or WKY versus the respective untreated rats;
# p<0.01 untreated SHR versus untreated WKY.
Table 2
Effect of LGF treatment on the structure of carotid arteries from WKYand
SHR
WKY
(n=8)
SHR
(n=8)
LGF-WKY
(n=6)
LGF-SHR
(n=8)
Internal diameter (Am) 696T14.2 657T69 703T19 726T40
Media thickness (Am) 68T1.6 73.5T12 71T2.8 65T12
SHR, spontaneously hypertensive rats; WKY, Wistar Kyoto rats. Rat
number is indicated in parentheses.
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 SHR, since LGF treatment did not modify vasodilatory
responses in WKY (Fig. 3A, B and C).
4. Discussion
The main finding of this work is the demonstration for
the first time that the antifibrotic mitogen LGF induces
striking changes in vascular composition and function,
together with a substantial blood pressure reduction in SHR.
These effects are achieved at a low dose of LGF within a
short period of treatment.
LGFtreatmentsignificantlyreducedbothSBPandDBPin
SHR, but not in WKY rats, suggesting that its effects are
specific for the hypertensive state. The fact that blood
pressure reduction was not accompanied by changes in HR
suggests that this factor might exert its effects by modifying
vascular structure and/or function in SHR, both of which are
known to be altered in hypertension [7,11,27]. This vascular
effect does not exclude other possible actions on the central
nervous system, including the baroreceptor reflex. LGF
treatment did not change gross carotid artery geometry, but
it significantly altered wall composition, modifying both
extracellular and cellular components of the vascular media
inSHR.Thus,medialcollagencontentwasreducedbynearly
50% by treatment, while there was an increase in VSMC
number. This inverse correlation between collagen and cell
number suggests that collagen in carotid arteries from SHR
was replaced by VSMC during LGF treatment. One of the
abnormalities of VSMC in hypertension is the increase in
polyploidy [10]. This is most likely related to a defect in
mitotic spindle cell cycle check point [28], so that cells
replicate their DNA but do not undergo cell division [29,30].
TheincreaseinVSMCnumber,togetherwiththereductionin
nuclear size induced by treatment, would suggest that LGF
reduces ploidy by stimulation of mitosis. This finding is not
surprising due to the reported mitogenic activity of LGF for
other cell types [12]. In WKY rats, LGF also increased
VSMC number but it did not modify collagen content. It is
therefore possible that LGF stimulates the proliferation of the
mature VSMC phenotype. This is of particular importance
since there is strong evidence that the switch of VSMC to an
immature phenotype plays a major role in a number of
vascular diseases such as atherosclerosis and hypertension
[31]. The striking antifibrotic and mitotic effects of LGF on
elasticarteriesofhypertensiveanimalswouldsuggestthatthe
actionofLGFisnotrestrictedtotheliver,andthatLGFmight
in fact be a pleiotropic agent with wider scope.
The present study demonstrates that LGF also has an
effect on elastin, the resilient protein of the vascular wall.
Elastin is a major component of conduit arteries [32] and,
together with collagen, is a key protein for vascular
Fig. 1. Transversal sections of carotid arteries from: (A) WKY, LGF-WKYand (B) SHR and LGF-SHR, stained with Massons trichromic. The nuclei appear in
dark blue, collagen is coloured in green, and the cytoplasm in red. Arrows identify hypertrophic nuclei in VSMC. Magnification 40. (C) Data on medial
collagen area and (D) smooth muscle cell number. * p<0.01 LGF-SHR versus untreated SHR.
# p<0.01 SHR versus WKY. n=6–8 rats per experimental
group.
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 mechanical properties [33]. It has been previously docu-
mented that the elastin content of large arteries is increased
by hypertension [34]. This was confirmed in our study,
where the desmosine content was significantly higher in
SHR carotid arteries compared to those of WKY. However,
newly synthesized elastin under pathological conditions
may not be as physiologically effective as that produced
during development [33]. In fact, we have previously
reported that in the IEL from SHR carotid [9] and resistance
arteries [22], elastin is abnormally organized, with a reduced
fenestra area. The present study demonstrates that total
elastin content was not significantly altered by LGF, but that
treatment enlarged fenestra area in SHR carotid arteries.
This is of special interest, since we have recently reported
that, in small arteries, the IEL fenestra area plays a more
prominent role in intrinsic vascular mechanical properties
than total elastin content [35]. Therefore, the increase in
fenestra size, together with the reduced collagen content,
induced by LGF treatment in SHR carotid arteries, is likely
to improve vascular mechanical properties in these vessels.
The above mentioned structural modifications were
accompanied by a significant increase in relaxation only in
SHR. The fact that this enhancement was observed in both
endothelium-dependent and independent agents, acting via
different pathways (cGMP, cAMP), suggests that LGF exerts
it effects through a general improvement of wall architecture.
It is known that fibrosis induced by excessive collagen
deposition influences arterial responses to vasodilators by
Fig. 2. (A) Confocal projections of the internal elastic lamina from WKY, LGF-WKY, SHR and LGF-SHR carotid arteries showing the fenestrae (green, elastin
autofluorescence. (B) Relative area occupied by fenestrae in IEL of carotid arteries from treated and untreated WKY and SHR. (C) Total desmosine content
determined by a specific radioimmunoassay in carotid arteries from treated and untreated WKY and SHR. * p<0.01 LGF-SHR versus untreated SHR.
# p<0.01 SHR versus WKY.
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 limiting the expansion of the vessel wall [11]. Moreover, the
fact that the first target for LGF action in liver is the
endothelium [18], does not exclude the possibility that the
positive effect of LGF on vasodilatation might be partially
due to an enhancement of vasoactive endothelial factors. In
studies related to this concept, other authors have detected
two specific receptors for ‘‘modified albumin’’ (albumin with
someligandbonds)inendothelialcells[36,37],thatresemble
LGF, an albumin–bilirubin complex [13]. Whether these
receptors bind LGF and initiate the regeneration cascade
remains to be determined. In addition, LGF could also
improve vasodilatation through an antioxidant effect, as
previously reported in hepatocytes, erythrocytes and myo-
cytes [38–40]. Safar and co-workers have highlighted the
importance of both the ECM and the endothelium for large
artery compliance [41]. Therefore, it is likely that LGF-
treatment might improve vascular mechanics through nor-
malization of both cellular function and the ECM.
We would like to stress the short period and low dose of
LGF treatment needed to reduce fibrosis, to increase
vasodilatory responses and to reduce blood pressure. This
is especially relevant if we compare it with classical
pharmacological treatments that usually require several
months to improve vascular structure and function [42–44].
Fig. 3. Vasodilator responses to: A) acetylcholine, B) forskolin, C) sodium nitroprusside (SNP) in carotid arteries from WKY, LGF-WKY, SHR and LGF-SHR.
Results are expressed as the meanTSEM. *p<0.01 LGF-SHR versus untreated SHR (two-way ANOVA). Number of animals is in parentheses.
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 In summary, two-week LGF-treatment induces striking
changes in elastic artery structure, function and blood
pressure in SHR. These results could open future research
to explore the vascular effects and mechanism of this
endogenous factor in order to determine its potential as an
antifibrotic and antihypertensive agent.
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